The Indian pharmaceutical industry processed ₹4.2 lakh crore worth of formulations in FY2024 — and more than 60% of that volume passed through third-party contract manufacturing organisations (CMOs). If you are a pharma entrepreneur, PCD franchise company, or established marketing company looking to expand your product portfolio, understanding how to choose and work with a contract manufacturer is your single most important business competency.
This guide covers everything you need to know — from regulatory framework to partner due diligence to product development timelines.
The Indian Third-Party Pharma Manufacturing Landscape
Why the Industry Runs on Third-Party Manufacturing
Third-party manufacturing (TPM) is not a cost-cutting measure for small companies. It is the structural model that allows India’s pharmaceutical industry to achieve its globally unmatched price-to-quality ratio.
The economics are straightforward:
| Model | Capital Required | Time to Market | Regulatory Risk |
|---|---|---|---|
| Own manufacturing facility | ₹25–150 crore | 3–5 years | Very High |
| Loan license (third-party) | ₹5–30 lakh | 30–90 days | Shared |
| PCD franchise (buy finished) | ₹2–10 lakh | 15–30 days | Low |
For most pharma marketing companies, loan license manufacturing provides the optimal balance: your brand, your pricing, your margins — without the ₹50+ crore capex of building a GMP facility.
India’s Manufacturing Hubs
While pharmaceutical manufacturing exists across India, five major clusters dominate:
- Baddi, Himachal Pradesh — India’s largest pharma cluster; WHO-GMP density; tax incentives
- Sikkim — GMP-compliant, tax-exempt zone
- Hyderabad, Telangana — API manufacturing concentration
- Ahmedabad, Gujarat — Generics and exports hub
- Bengaluru, Karnataka — Biotech and specialty pharma
Regulatory Framework for Third-Party Manufacturing in India
The Drugs & Cosmetics Act, 1940
All pharmaceutical manufacturing in India is governed by the Drugs & Cosmetics Act, 1940 and Rules, 1945. Key sections relevant to third-party manufacturing:
- Section 18: Prohibition on manufacture of drugs without license
- Section 18C: Loan license — allows manufacture at another’s licensed premises
- Schedule M: GMP requirements (India’s WHO-GMP implementation)
- Schedule H/H1: Prescription drug classifications
License Types You Need to Know
| License | Issued By | Purpose |
|---|---|---|
| Drug Manufacturing License (Form 25/28) | State Drug Authority | Authorises manufacture at own/loan premises |
| Loan License (Form 25A/28A) | State Drug Authority | Authorises your brand to be manufactured at CMO’s facility |
| Wholesale Drug License (Form 20/21) | State Drug Authority | Required for distribution |
| CDSCO Registration | Central Drug Authority | For Schedule X drugs, new molecules |
Choosing the Right Contract Manufacturing Partner
This is the decision that will define your brand’s quality, reliability, and ultimately, its success. Here is the structured evaluation framework used by professional pharma procurement teams:
Phase 1: Desk Audit (Before Visiting the Facility)
Request and verify these documents:
- Current Drug Manufacturing License — verify the license number with the state drug authority online portal
- WHO-GMP Certificate — check issue date, expiry, and scope (which dosage forms are covered)
- ISO 9001:2015 Certificate — cross-verify with the certifying body
- List of Existing Clients — ask for 2–3 reference contacts you can call
- Sample COA and BMR — assesses documentation quality and completeness
Phase 2: Facility Audit
Visit the facility with this checklist:
FACILITY AUDIT CHECKLIST — THIRD-PARTY MANUFACTURER EVALUATION
DOCUMENTATION
☐ Drug manufacturing license displayed and current
☐ SOP register maintained and approved
☐ Change control records available for review
☐ Deviation and CAPA logs accessible
MANUFACTURING AREA
☐ Positive/negative pressure differentials maintained
☐ HVAC validation records available
☐ Beta-Lactam / Non-Beta-Lactam segregation (if applicable)
☐ Cleaning validation SOPs in place
☐ Personnel gowning procedures followed
QUALITY CONTROL LABORATORY
☐ HPLC calibration records current
☐ Reference standard management system in place
☐ Analyst training records maintained
☐ OOS procedure posted and understood by staff
WAREHOUSE & COLD CHAIN
☐ Temperature-controlled storage for thermolabile items
☐ Quarantine area clearly marked and locked
☐ Approved Vendor List (AVL) accessible
☐ Raw material testing records available
Phase 3: Capability Assessment
Verify that the manufacturer can actually produce your specific product:
| Question | Why It Matters |
|---|---|
| “Have you manufactured this formulation before?” | Existing validation reduces your timeline and risk |
| “What is your average batch size for this category?” | Ensures your MOQ is economically viable for them |
| “What is your current production capacity utilisation?” | An overloaded CMO will deprioritise your batches |
| “Do you have stability chambers for accelerated + real-time?” | Essential for registering your product |
View manufacturing details for azithromycin-oral-solution
Product Development & Formulation
From Brief to Batch: The Development Timeline
Most brand owners underestimate how long product development takes. Here is a realistic timeline for launching a new pharma product through third-party manufacturing:
- Brief & Feasibility (Week 1–2): Product name, strength, dosage form, target market, reference innovator product
- Formulation Development (Week 3–10): Prototype batches, preliminary stability screening, taste masking (for paediatric)
- Analytical Method Development (Week 4–10): HPLC method development, method validation
- Regulatory Support (Week 8–14): Technical documentation for drug licensing
- Stability Studies Begin (Month 3+): ICH Q1A protocols — accelerated 6 months, real-time 12–24 months
- Pilot Scale Batch (Month 4–5): Scale-up from lab to production scale
- License Application (Month 4–6): State drug authority application with full dossier
- Commercial Batch 1 (Month 5–7): After license receipt
For products already on the approved list of an established CMO like Saar Biotech — where stability data already exists and the formulation is validated — this timeline compresses to 30–45 working days from contract execution to first dispatch.
High-Margin Dosage Forms to Prioritise
Not all pharma products are created equal. These dosage forms consistently command the highest margins and lowest competition in Indian pharma marketing:
- Nasal Sprays — specialty manufacturing capability, high perceived value, growing ENT market
- Vitamin D Nano-Shots — nutraceutical-pharma hybrid, premium pricing, cholecalciferol boom
- Oral Suspensions (Paediatric) — repeat prescription, brand loyalty, anti-infective + antipyretic
- Gel-Based Topicals — dermatology fast-growing; specialty manufacturer selection critical
View manufacturing details for sodium-chloride-benzalkonium-nasal-spray
Pricing, MOQ, and Commercial Terms
Understanding CMO Pricing Models
Contract manufacturers typically price on one of three models:
Model A: Per-Unit Cost (Most Common) A per-bottle/per-strip/per-vial rate inclusive of raw materials, labour, and overhead. Packaging (primary and secondary) may be CMO-supplied or buyer-supplied.
Model B: Conversion Charges Only You supply raw materials; the CMO charges only for manufacturing conversion. Useful when you have existing API supplier relationships or import APIs directly.
Model C: Milestone-Based Development + Supply Upfront development fee for new products, followed by a per-unit supply price. Common for specialty or novel formulations.
What to Include in Your Manufacturing Agreement
A robust third-party manufacturing agreement must include:
- Intellectual Property clauses — who owns the formula, dossier, and stability data?
- Exclusivity terms — is your formulation available to competing brands?
- Quality specifications — master formula attached, COA format specified
- Rejection and return policy — what happens to non-conforming batches?
- Lead time guarantees — with penalty clauses for delay
- Regulatory cooperation — CMO’s obligation to support your drug license
View manufacturing details for levosalbutamol-ambroxol-guaiphenesin-syrup
Building a Long-Term CMO Partnership
The most successful pharma marketing companies in India treat their contract manufacturer not as a vendor, but as a strategic manufacturing partner. This means:
- Annual performance reviews — formal assessment of quality metrics, delivery timelines, regulatory compliance
- Forecasting transparency — share 3–6 month rolling sales forecasts so the CMO can plan raw material procurement
- Early involvement in new product decisions — let your CMO’s technical team evaluate feasibility before you commit to the market
- Regulatory co-investment — some brand owners co-fund stability studies and dossier development for faster licensing
The brands that grow fastest in pharma are those that leverage their manufacturing partner’s regulatory expertise, not those that treat manufacturing as a commodity service.
Conclusion
Third-party pharmaceutical manufacturing is the backbone of India’s ₹4+ lakh crore pharmaceutical industry. Done right, it gives your brand access to world-class manufacturing capability, regulatory expertise, and product development support — at a fraction of the cost of building your own facility.
The key is choosing a partner who matches your quality standards, has the specific manufacturing capabilities you need, and operates with the regulatory discipline that protects your brand and your patients.
At Saar Biotech, we have been the manufacturing partner of choice for 2,000+ pharma brands across India — from first-time entrepreneurs launching their PCD business to established companies expanding their specialty portfolio. Our WHO-GMP certified facility in Baddi specialises in oral liquids, suspensions, nasal sprays, and gels — the high-margin dosage forms that differentiate modern pharma brands.
Ready to launch your brand or expand your product range? Reach out for a free consultation and product feasibility assessment.
Frequently Asked Questions
What is the difference between a PCD pharma company and a third-party manufacturer?
A PCD (Propaganda Cum Distribution) pharma company is a marketing entity that holds the drug license for branded products and distributes them through a franchise network. A third-party manufacturer (CMO/TPM) is the facility that physically manufactures the products on behalf of the PCD company under a loan license or manufacturing agreement. Saar Biotech is the manufacturer; you are the PCD/marketing company.
What is the minimum order quantity (MOQ) at Saar Biotech?
MOQs vary by product and dosage form. For liquid orals and suspensions, MOQs typically start at 5,000 units (bottles) per SKU. For nasal sprays and specialty formats, MOQ discussions are held based on the specific product and fill volume. We are flexible for long-term partners and first-time brand launches — contact our business development team to discuss your specific requirements.
How long does it take from contract signing to first batch dispatch?
For products already on our approved manufacturing list with existing stability data, the timeline from contract execution to first batch is typically 30–45 working days, covering artwork approval, regulatory NOC issuance, raw material procurement, and production scheduling. New products requiring formulation development or stability studies take 3–6 months additional.
Do you provide support for drug licensing and regulatory filings?
Yes. Our regulatory affairs team assists with state drug license applications (Form 25/25A), CDSCO filings, DCGI scheduling, and NOC issuance from our facility. We prepare complete technical dossiers including stability data, manufacturing process descriptions, and analytical method validations. This support is included in our manufacturing partnership agreements.
Can I do private labelling for export markets?
Yes. Saar Biotech supplies to pharmaceutical companies exporting to South-East Asia, Middle East, and African markets. Products for export markets can be manufactured against WHO Prequalification standards or specific country regulatory requirements. Export COAs are issued in the required format. Contact us with your target market specifications.
What is the difference between loan licence manufacturing and own manufacturing?
Loan license manufacturing (Section 18C of the Drugs & Cosmetics Act) allows a brand owner (licensee) to manufacture products at a licensed third-party facility. The licensee holds their own state drug manufacturing license but uses the CMO's facility. Own manufacturing requires the brand to own and operate their own GMP facility. Third-party/loan license is the preferred model for most pharma marketing companies as it eliminates capital expenditure on facility construction and maintenance.
Contact Saar Biotech’s Business Development Team: quotation@saarbiotech.com | +91 9357690454 | saarbiotech.in